Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]
Discontinued
Reference number: GID-TA10110
Following on from advice received from the company, the timelines for this appraisal remain to be confirmed. NICE has decided to suspend this appraisal on its current work programme, however, as this appraisal has been referred, we will continue to monitor any development and will update interested parties if and when the situation changes .